Koyfin Home > Directory > Health Care > Revance Therapeutics > Capital Expenditures

Revance Therapeutics Capital Expenditures Chart (RVNC)

Revance Therapeutics annual/quarterly Capital Expenditures from 2012 to 2020.
  • Revance Therapeutics Capital Expenditures for the quarter ending June 06, 2020 was $-1m a -158.54% increase of 1m year over year
  • Revance Therapeutics Capital Expenditures for the last 12 months ending June 06, 2020 was $-3m a -58.16% increase of 2m year over year
  • Revance Therapeutics Annual Capital Expenditures for 2019 was $-3m a -115.90% increase of 4m from 2018
  • Revance Therapeutics Annual Capital Expenditures for 2018 was $-7m a 63.88% decrease of -4m from 2017
  • Revance Therapeutics Annual Capital Expenditures for 2017 was $-3m a 33.86% decrease of -1m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Capital Expenditures Data

06/2020$-1m
03/2020$-1m
12/2019$0m
09/2019$-1m
06/2019$0m
03/2019$-1m
12/2018$-2m
09/2018$-3m
06/2018$-1m
03/2018$-1m

Annual RVNC Capital Expenditures Data

2019$-3m
2018$-7m
2017$-3m
2016$-2m
2015$-3m
2014$-7m
2013$-6m
2012$0m
2011$0m